Amphastar PharmaceuticalsAMPH
AMPH
About: Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Employees: 2,028
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
90% more call options, than puts
Call options by funds: $637K | Put options by funds: $336K
3.36% less ownership
Funds ownership: 73.14% [Q4 2024] → 69.78% (-3.36%) [Q1 2025]
9% less funds holding
Funds holding: 262 [Q4 2024] → 239 (-23) [Q1 2025]
15% less repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 94
26% less capital invested
Capital invested by funds: $1.31B [Q4 2024] → $964M (-$342M) [Q1 2025]
34% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 50
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
16%
upside
Avg. target
$32
25%
upside
High target
$35
36%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
JP Morgan Ekaterina Knyazkova | 16%upside $30 | Neutral Downgraded | 12 May 2025 |
Wells Fargo Cerena Chen | 36%upside $35 | Overweight Maintained | 8 May 2025 |
Piper Sandler David Amsellem | 24%upside $32 | Neutral Maintained | 21 Mar 2025 |
Financial journalist opinion
Neutral
Accesswire
3 weeks ago
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 22, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5th, 2025, at 2:00 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
Positive
Seeking Alpha
1 month ago
Amphastar Pharmaceuticals: Navigating Through An Inflection Year
Amphastar Pharmaceuticals posted Q1 results last week that beat the bottom-line consensus. The stock appears cheap at under eight times forward earnings, but the company is going through an 'inflection year' with flat revenue growth and declining profits. Growth should return in 2026 thanks to upcoming product launches. Is the stock cheap enough to buy the recent dip in the shares?
Neutral
Accesswire
1 month ago
Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 9, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 2025 Bank of America Health Care Conference on Wednesday, May 14th, 2025, at 1:40 pm PT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
Positive
Zacks Investment Research
1 month ago
Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neutral
Seeking Alpha
1 month ago
Amphastar Pharmaceuticals Inc. (AMPH) Q1 2025 Earnings Call Transcript
Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer & Executive Vice President of Finance Tony Marrs - Executive Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants David Amsellem - Piper Sandler Cerena Chen - Wells Fargo Jason Gerberry - Bank of America Ekaterina Knyazkova - JPMorgan Operator Greetings and welcome to the Amphastar Pharmaceuticals First Quarter Earnings Call. At this time, all participants are in a listen-only mode.
Positive
Zacks Investment Research
1 month ago
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $1.04 per share a year ago.
Neutral
Accesswire
1 month ago
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
Reports Net Revenues of $170.5 Million for the Three Months Ended March 31, 2025 RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2025. First Quarter Highlights Net revenues of $170.5 million for the first quarter GAAP net income of $25.3 million, or $0.51 per share, for the first quarter Adjusted non-GAAP net income of $36.9 million, or $0.74 per share, for the first quarter Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We are confident in the potential of our portfolio, particularly with the growth of BAQSIMI® and Primatene MIST®, and the promising pipeline of biosimilars and proprietary products.
Neutral
Zacks Investment Research
1 month ago
Is the Options Market Predicting a Spike in Amphastar (AMPH) Stock?
Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately.
Neutral
Accesswire
1 month ago
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31, 2025, after the market closes on Wednesday, May 7th, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Neutral
Accesswire
2 months ago
Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 3, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th, 2025, at 1:30 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
Charts implemented using Lightweight Charts™